Corbus Pharmaceuticals Holdings Balance Sheet Health
Financial Health criteria checks 5/6
Corbus Pharmaceuticals Holdings has a total shareholder equity of $125.5M and total debt of $10.8M, which brings its debt-to-equity ratio to 8.6%. Its total assets and total liabilities are $152.0M and $26.4M respectively.
Key information
8.6%
Debt to equity ratio
US$10.82m
Debt
| Interest coverage ratio | n/a |
| Cash | US$147.03m |
| Equity | US$125.54m |
| Total liabilities | US$26.44m |
| Total assets | US$151.98m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 3371's short term assets ($148.3M) exceed its short term liabilities ($24.0M).
Long Term Liabilities: 3371's short term assets ($148.3M) exceed its long term liabilities ($2.5M).
Debt to Equity History and Analysis
Debt Level: 3371 has more cash than its total debt.
Reducing Debt: 3371's debt to equity ratio has increased from 0.2% to 8.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3371 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 3371 has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 3.4% each year.